B-Cell Lymphoma Specific Neutra™ Antibody Products

Are you grappling with prolonged timelines in B-cell malignancy drug development or challenges in generating high-specificity antibodies? Creative Biolabs' B-cell lymphoma-specific neutra™ antibody products leverage advanced protein engineering and high-throughput functional validation to deliver rigorously optimized reagents, empowering rapid discovery of therapeutic candidates and reliable biomarker analysis.

Introduction to B-Cell Lymphoma

B-cell lymphoma, a heterogeneous group of malignancies arising from aberrant B-lymphocytes, represents over 85% of non-Hodgkin lymphomas. These cancers are characterized by dysregulated proliferation and survival of mature B-cells, often driven by genetic mutations, chromosomal translocations, or disrupted signaling pathways. Understanding the molecular architecture and pathogenic mechanisms of B-cell lymphoma is critical for developing targeted therapies.

• Basic Information

B-cell lymphoma encompasses subtypes such as diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL). Malignant B-cells typically overexpress surface markers like CD19, CD20, CD22, and CD79b, making these proteins ideal therapeutic targets. Disease progression correlates with genetic alterations in BCL2, MYC, and TP53, as well as dysregulated apoptosis and cell-cycle pathways.

• Structure

Key structural components of B-cell lymphoma include membrane-bound immunoglobulins (BCR complex) and co-stimulatory receptors. The BCR comprises surface Ig non-covalently linked to CD79a/CD79b heterodimers, which transmit survival signals. Additionally, the tumor microenvironment (TME) facilitates lymphoma progression through chemokine-mediated interactions (e.g., CXCR4/CXCL12) and stromal cell adhesion.

• Related Signaling Pathways

Constitutively activated pathways in B-cell lymphoma include:

-BCR Signaling: Sustained activation of SYK, BTK, and PI3K promotes proliferation and survival.

-NF-κB Pathway: Critical for evading apoptosis, driven by mutations in CARD11 or MYD88.

-JAK-STAT: Mediates cytokine-driven growth in subtypes like primary mediastinal B-cell lymphoma.

-Apoptosis Regulation: Overexpression of anti-apoptotic BCL2 family proteins confers resistance to cell death.

Fig. 1 Metabolic pathways in B-cell lymphoma.¹

• Related Diseases

B-cell lymphoma manifests as indolent (e.g., FL) or aggressive (e.g., DLBCL) malignancies, with clinical outcomes influenced by molecular subtyping. Complications include organ infiltration, cytopenias, and immunosuppression. Relapsed/refractory cases remain a major therapeutic challenge, highlighting the need for precision-targeted interventions.

Applications of Neutralizing Antibodies in B-Cell Lymphoma

• Targeted Therapy Development

Neutralizing antibodies form the cornerstone of precision therapies. Anti-CD20 monoclonal antibodies combined with chemotherapy improve survival in DLBCL. Next-gen anti-CD19 CAR-T therapies achieve remission in refractory cases by redirecting T-cell cytotoxicity.

• Immune Checkpoint Modulation

Antibodies blocking PD-1/PD-L1 axis counteract TME-mediated immunosuppression, enhancing endogenous anti-tumor responses. Combination regimens with anti-CD20 antibodies amplify efficacy in FL and MCL.

• Diagnostic and Prognostic Biomarkers

Antibodies enable flow cytometry-based lymphoma subtyping (e.g., CD5⁺ vs. CD10⁺ classification) and minimal residual disease (MRD) monitoring. Immunohistochemistry with anti-BCL6 or anti-MUM1 antibodies refines molecular stratification.

• Preclinical Research Tools

Anti-CXCR4 antibodies model metastasis inhibition, while anti-BTK antibodies validate pathway inhibition in xenografts. Neutralizing antibodies also facilitate functional studies of apoptotic priming in drug-resistant clones.

Our Anti-B-Cell Lymphoma Antibody Products

Neutralizing antibodies against B-cell lymphoma antigens disrupt oncogenic signaling and induce antibody-dependent cellular cytotoxicity (ADCC) or phagocytosis (ADCP). Key targets include:

-CD20: Antibodies bind distinct epitopes to deplete malignant B-cells via complement-dependent cytotoxicity (CDC).

-CD19: Bispecific antibodies engage T-cells for tumor lysis, while antibody-drug conjugates (ADCs) deliver cytotoxic payloads.

-CD79b: ADCs targeting this BCR component internalize rapidly, enhancing tumor-specific drug delivery.

Novel anti-CD22 antibodies block pro-survival signaling, while anti-CD47 antibodies disrupt "don't eat me" signals to boost macrophage activity.

Creative Biolabs' B-cell lymphoma-specific neutra™ antibody products combine unmatched specificity and functional validation to drive breakthroughs in lymphoma research and drug development. Our portfolio spans neutralizing antibodies against CD19, CD20, CD22, and immune checkpoints, engineered for superior performance in in vitro and in vivo models. Contact our scientific team today to explore customized solutions for your B-cell lymphoma project.

REFERENCE

1. Kluckova, Katarina, Annalisa D'Avola, and John Charles Riches. "Advances in understanding of metabolism of B-cell lymphoma: implications for therapy." Cancers 14.22 (2022): 5552. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/cancers14225552